title: Activation of BKCa channels via cyclic AMP- and cyclic GMP-dependent protein kinases by eugenosedin-A in rat basilar artery myocytes.
abstract: OBJECTIVE
  The study investigated whether eugenosedin-A, a 5-hydroxytryptamine and alpha/beta adrenoceptor antagonist, enhanced delayed-rectifier potassium (K(DR))- or large-conductance Ca(2+)-activated potassium (BK(Ca))-channel activity in basilar artery myocytes through cyclic AMP/GMP-dependent and -independent protein kinases.
  
  
  METHODS
  Cerebral smooth muscle cells (SMCs) were enzymatically dissociated from rat basilar arteries. Conventional whole cell, perforated and inside-out patch-clamp electrophysiology was used to monitor K(+)- and Ca(2+)-channel activities.
  
  
  RESULTS
  Eugenosedin-A (1 microM) did not affect the K(DR) current but dramatically augmented BK(Ca) channel activity in a concentration-dependent manner. Increased BK(Ca) current was abolished by charybdotoxin (ChTX, 0.1 microM) or iberiotoxin (IbTX, 0.1 microM), but not affected by a small-conductance K(Ca) blocker (apamin, 100 microM). BK(Ca) current activation by eugenosedin-A was significantly inhibited by an adenylate cyclase inhibitor (SQ 22536, 10 microM), a soluble guanylate cyclase inhibitor (ODQ, 10 microM), competitive antagonists of cAMP and cGMP (Rp-cAMP, 100 microM and Rp-cGMP, 100 microM), and cAMP- and cGMP-dependent protein kinase inhibitors (KT5720, 0.3 microM and KT5823, 0.3 microM). Eugenosedin-A reversed the inhibition of BK(Ca) current induced by the protein kinase C activator, phorbol myristyl acetate (PMA, 0.1 microM). Eugenosedin-A also prevented BK(Ca) current inhibition induced by adding PMA, KT5720 and KT5823. Moreover, eugenosedin-A reduced the amplitude of voltage-dependent L-type Ca(2+) current (I(Ca,L)), but without modifying the voltage-dependence of the current.
  
  
  CONCLUSIONS
  Eugenosedin-A enhanced BK(Ca) currents by stimulating the activity of cyclic nucleotide-dependent protein kinases. Physiologically, this activation would result in the closure of voltage-dependent calcium channels and thereby relax cerebral SMCs.
authors: Department and Graduate Institute of Pharmacology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors: B-N
authors: BN
authors: Wu
authors: C-F
authors: CF
authors: Chen
authors: Y-R
authors: YR
authors: Hong
authors: S-L
authors: SL
authors: Howng
authors: Y-L
authors: YL
authors: Lin
authors: I-J
authors: IJ
authors: Chen
mesh_terms: D018674:Adrenergic Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001488:Basilar Artery / Q000166:cytology / Q000187:drug effects; D017868:Cyclic AMP-Dependent Protein Kinases / Q000187:drug effects* / Q000378:metabolism; D017869:Cyclic GMP-Dependent Protein Kinases / Q000187:drug effects* / Q000378:metabolism; D051668:Delayed Rectifier Potassium Channels / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D005260:Female; D051036:Large-Conductance Calcium-Activated Potassium Channels / Q000187:drug effects / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism; D018408:Patch-Clamp Techniques; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D015398:Signal Transduction
chemical_list: D018674:Adrenergic Antagonists; D051668:Delayed Rectifier Potassium Channels; D051036:Large-Conductance Calcium-Activated Potassium Channels; D010879:Piperazines; D012702:Serotonin Antagonists; C496985:eugenosedin-A; D017868:Cyclic AMP-Dependent Protein Kinases; D017869:Cyclic GMP-Dependent Protein Kinases
references: Am J Physiol Cell Physiol. 2000 Feb;278(2):C235-56
references: 10666018
references: Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H1085-94
references: 17056667
references: Br J Pharmacol. 2001 Sep;134(2):265-74
references: 11564644
references: Am J Physiol Cell Physiol. 2001 Nov;281(5):C1512-23
references: 11600414
references: Circ Res. 2002 Oct 4;91(7):610-7
references: 12364389
references: Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14560-5
references: 12391293
references: Am J Physiol Lung Cell Mol Physiol. 2004 Jan;286(1):L149-55
references: 14514518
references: Am J Physiol Heart Circ Physiol. 2004 Feb;286(2):H610-8
references: 14563665
references: Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1088-100
references: 14592941
references: Pharmacology. 2004 Jun;71(2):91-101
references: 15118348
references: J Pharmacol Exp Ther. 1968 Jan;159(1):129-45
references: 4296170
references: Science. 1992 Apr 24;256(5056):532-5
references: 1373909
references: Acta Physiol Hung. 1991;78(3):201-9
references: 1814162
references: Am J Physiol. 1993 Jul;265(1 Pt 1):C299-303
references: 8338137
references: Trends Pharmacol Sci. 1994 Oct;15(10):370-4
references: 7809952
references: Am J Physiol. 1995 Apr;268(4 Pt 1):C799-822
references: 7733230
references: Science. 1995 Oct 27;270(5236):633-7
references: 7570021
references: Stroke. 1996 Sep;27(9):1603-7; discussion 1607-8
references: 8784136
references: Am J Physiol. 1996 Oct;271(4 Pt 1):C1203-11
references: 8897826
references: Am J Physiol. 1997 Feb;272(2 Pt 2):H904-12
references: 9124454
references: Naunyn Schmiedebergs Arch Pharmacol. 1998 Jun;357(6):705-8
references: 9686949
references: Br J Pharmacol. 2005 Nov;146(6):862-71
references: 16151435
references: Mol Pharmacol. 2006 Sep;70(3):977-85
references: 16754782
references: Circ Res. 2000 Apr 28;86(8):897-905
references: 10785513